L. Huang

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib

M. Lacouture, G. Dranitsaris, M. Vincent, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

The expression and clinical significance of B7-H3 and miR-145 in lung cancer patients with malignant pleural effusion.

L. Huang, 2020, European review for medical and pharmacological sciences.

The Importance of the Change Point Recognition in the Landmark Analysis of Immuno-oncology Clinical Trial with the Delayed Treatment Effect

L. Huang, N. Ting, 2020 .

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

Chun-Fang Xu, L. Cardon, V. Mooser, 2010, British Journal of Cancer.

LBA8A PHASE III RANDOMIZED, DOUBLE-BLIND, TRIAL COMPARING SORAFENIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER (RESILIENCE)

J. Bergh, C. Hudis, W. Gradishar, 2014 .

Decreased expression of SorCS1 in colorectal cancer: An independent predictor of poor prognosis.

M. Huang, Xiaolin Wang, Meijin Huang, 2019, Neoplasma.

Characterizing the Activation of the Wnt Signaling Pathway in Hilar Cholangiocarcinoma Using a Tissue Microarray Approach

J. Lai, L. Liang, J. Liang, 2016, European journal of histochemistry : EJH.

Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial

R. Goldberg, H. Lenz, J. Tabernero, 2016 .

Radium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

F. Saad, J. Carles, M. Wirth, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of hepatic impairment on sorafenib pharmacokinetics: Results of a multicenter, open-label, single-dose, phase I trial.

C. Lathia, A. Mazzu, J. Lettieri, 2011, Journal of Clinical Oncology.

The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.

Z. Shao, C. Chen, L. Huang, 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.

M. Lacouture, G. Dranitsaris, M. Vincent, 2012 .

LBA48 DUBLIN-3 (BPI-2358-103): A global phase (Ph) III trial with the plinabulin/docetaxel (Plin/Doc) combination vs. Doc in 2nd/3rd Line NSCLC patients (pts) with EGFR-wild type (wt) progressing on a prior platinum-based regimen

L. Du, R. Mohanlal, Y. Sun, 2021, Annals of Oncology.